Critical limb ischaemia and the response to bone marrow-derived cell therapy according to tcPO2 measurement.

Date publication

janvier 2017

Journal

VASA. Zeitschrift fur Gefasskrankheiten

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe

Tous les auteurs :
Maufus M, Antoinette Sevestre-Pietri M, Sessa C, Pignon B, Egelhofer H, Dupas S, Nguyen P, Genty C, Pernod G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27869551

Résumé

Cell therapy is an emerging potential biotherapy for critical limb ischaemia (CLI) patients who are not eligible for revascularization. However, the findings on this technique's efficacy are inconsistent. Trials investigating this topic focused on the more severe CLI patients who were often beyond any therapy. Therefore, identifying those who may truly benefit from cell transplantation is now warranted. To this end, we studied the prognostic value of tcPO2 for major amputation after 1 year in patients treated with bone marrow-derived cells.

Référence

VASA. 2017 Jan;46(1):23-28